These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 25953735

  • 1. Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.
    Pawlowska M, Bogiel M, Duda J, Sieradzki E.
    Eur J Clin Pharmacol; 2015 Jun; 71(6):699-705. PubMed ID: 25953735
    [Abstract] [Full Text] [Related]

  • 2. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.
    Cho CK, Byeon JY, Kang P, Park HJ, Ko E, Mu CY, Jang CG, Lee SY, Lee YJ.
    Arch Pharm Res; 2023 Feb; 46(2):111-116. PubMed ID: 36564599
    [Abstract] [Full Text] [Related]

  • 3. Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.
    Byeon JY, Cho CK, Kang P, Kim SH, Jang CG, Lee SY, Lee YJ.
    Arch Pharm Res; 2023 Aug; 46(8):713-721. PubMed ID: 37728834
    [Abstract] [Full Text] [Related]

  • 4. Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone.
    Cho CK, Byeon JY, Kang P, Park JI, Jang CG, Lee SY, Choi CI, Bae JW, Lee YJ.
    Arch Pharm Res; 2023 Jan; 46(1):59-64. PubMed ID: 36542291
    [Abstract] [Full Text] [Related]

  • 5. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J.
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [Abstract] [Full Text] [Related]

  • 6. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
    Kirchheiner J, Müller G, Meineke I, Wernecke KD, Roots I, Brockmöller J.
    J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
    [Abstract] [Full Text] [Related]

  • 7. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
    Chung H, Lee H, Han HK, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS.
    Drug Des Devel Ther; 2015 Oct; 9():2609-16. PubMed ID: 25999694
    [Abstract] [Full Text] [Related]

  • 8. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
    Koh A, Pak KC, Choi HY, Ryu S, Choi SE, Kim KS, Bae KS, Lim HS.
    J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
    [Abstract] [Full Text] [Related]

  • 9. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
    Dalmadi B, Leibinger J, Szeberényi S, Borbás T, Farkas S, Szombathelyi Z, Tihanyi K.
    Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
    [Abstract] [Full Text] [Related]

  • 10. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
    Bramness JG, Skurtveit S, Gulliksen M, Breilid H, Steen VM, Mørland J.
    Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435
    [Abstract] [Full Text] [Related]

  • 11. Considerable interindividual variation in the pharmacokinetics of tolperisone HCl.
    Bae JW, Kim MJ, Park YS, Myung CS, Jang CG, Lee SY.
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):110-3. PubMed ID: 17323790
    [Abstract] [Full Text] [Related]

  • 12. Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers.
    Borobia AM, Novalbos J, Guerra-López P, López-Rodríguez R, Tabares B, Rodríguez V, Abad-Santos F, Carcas AJ.
    Pharmacol Res; 2009 Jun; 59(6):393-8. PubMed ID: 19429471
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects.
    Gong J, Hansen L, Iacono L.
    Drug Metab Dispos; 2018 Mar; 46(3):316-325. PubMed ID: 29311135
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram.
    Fudio S, Borobia AM, Piñana E, Ramírez E, Tabarés B, Guerra P, Carcas A, Frías J.
    Eur J Pharmacol; 2010 Jan 25; 626(2-3):200-4. PubMed ID: 19840783
    [Abstract] [Full Text] [Related]

  • 17. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers.
    Gawrońska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, Drozdzik M.
    Eur J Clin Pharmacol; 2012 Sep 25; 68(9):1267-74. PubMed ID: 22418828
    [Abstract] [Full Text] [Related]

  • 18. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI, Martín-Vílchez S, Abad-Santos F.
    Basic Clin Pharmacol Toxicol; 2018 Jun 25; 122(6):596-605. PubMed ID: 29325225
    [Abstract] [Full Text] [Related]

  • 19. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
    Nazir S, Iqbal Z, Ahmad L, Ahmad S.
    Pak J Pharm Sci; 2016 May 25; 29(3):887-94. PubMed ID: 27166533
    [Abstract] [Full Text] [Related]

  • 20. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E.
    Pharmacol Res; 2004 Aug 25; 50(2):195-200. PubMed ID: 15177309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.